Why the study?
Do NSAIDs or COX-2 inhibitors interact with the antithrombotic effects of aspirin in a rat arterial thrombosis model?
Do NSAIDs or COX-2 inhibitors interact with the antithrombotic effects of aspirin in a rat arterial thrombosis model?
Certain NSAIDs and COX-2 inhibitors (ibuprofen, celecoxib, rofecoxib) may attenuate the antithrombotic efficacy of aspirin, while others (diclofenac, flurbiprofen) do not.
Answers are grounded in this paper and cite their sources.
These NSAID-aspirin interactions in rats should not change practice; leaves open translation to human thrombosis prevention.
Recent in vitro studies, clinical trials and epidemiological studies have suggested possible interactions between aspirin and other cyclo-oxygenase (COX) inhibitors, such as ibuprofen of the COX-2 inhibitors celecoxib and rofecoxib. The objective of this study was to test the effects of aspirin (1, 2.5 and 5 mg/kg), and ibuprofen (4 and 15 mg/kg), diclofenac (2.5 mg/kg), flurbiprofen (2 mg/kg), celecoxib (7.5 mg/kg), and rofecoxib (1 mg/kg), alone or combined on a rat model of arterial thrombosis. Drugs were given orally daily for 7 days, before insertion of an arterio-venous shunt thrombosis system, left in place for 15 min. Main parameter was thrombus weight. Five to 12 rats were used per experiment, and 35 controls overall. Aspirin inhibited thrombus formation in a dose-dependent manner. All NSAIDS given alone also inhibited thrombus formation to approximately the same level as aspirin 1 mg/kg/day. Ibuprofen, celecoxib and rofecoxib inhibited the effects of aspirin, but not diclofenac or flurbiprofen. The interactions with aspirin do not seem to affect all NSAIDs to equal levels. The clinical impact of this needs to be confirmed in adequately powered clinical trials or pharmaco-epidemiological studies.
No takes yet. Share an insight, caveat, or question.
Umar et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: